CRISPR gene editing has had a big decade. The technology, which earned two of its discovers a Nobel Prize in 2020, can target and edit genes more easily than its predecessors. Still, as tantalizing (and controversial) as the technologys been over the years, its mostly been developed in the lab.
Thats changing now as a growing number of clinical trials are beginning to test gene therapies in humans.
Early CRISPR trials have focused on hereditary blindness and diseases of the blood, including cancer, sickle cell anemia, and beta thalassemia.
Although cutting-edge, the therapies can be costly and intense. In one trial for sickle cell anemia, doctors remove cells from the body, edit them in a dish, and then infuse them back into the patient. In another trial, practitioners inject the gene editing system directly into target tissues in the eye.
Such approaches wont work as readily for other diseases. So researchers and doctors are looking for a general delivery method, like any other medication. Now, a clinical trial from University College London (UCL) has taken a step in that direction.
Participants in the trial suffer from a condition called hereditary transthyretin amyloidosis, in which a mutated gene produces a malformed protein (transthyretin) that builds up in and damages the heart and nerves. The disease is eventually fatal.
Patients received a single infusion of a CRISPR-based therapy into their bloodstream. Blood carried the therapy to the liver, where it switched off the mutated gene and curtailed production of the errant protein. Though the Phase 1 trial was small, the approach had strong results relative to existing options. And it hints at the possibility other genetic diseases may be treated in a similar fashion in the future.
The University of California, Berkeleys Jennifer Doudna, who shared the Nobel Prize for CRISPR, cofounded Intellia, the company that, alongside fellow biotech company Regeneron, developed the treatment (NTLA-2001) used in the UCL trial.
This is a major milestone for patients, Doudna said. While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place.
The therapy is made up of three parts. A tiny bubble of fat, called a lipid nanoparticle, carries a payload of CRISPR machinery: a strand of guide RNA and a sequence of mRNA coding for the Cas9 protein.
Billions of these CRISPR-carrying nanoparticles are infused into the bloodstream, making their way to the liver, the source of the dysfunctional protein. The mRNA instructs the cells to produce the Cas9 protein (CRISPRs genetic scissors) which then links up with the guide RNA, seeks out the target gene, and snips it.
The cell repairs the DNA at the site of the break, but imperfectly, switching the gene off and shutting down production of the problematic protein.
Interim trial results, reported in the New England Journal of Medicine last weekend, were very encouraging. The trials six patients, who received either a low or high dose, reported no serious side effects. Meanwhile, production of the target protein declined by up to 96 percent (and an average of 87 percent) in those given the high dose.
The disease, which affects some 50,000 people worldwide, was untreatable until recently.
Existing drugs, approved by the FDA in 2018, silence the mRNA that produces the malformed thyretin protein, instead of altering its gene. They reduce protein production some 80 percent and keep people alive longer, but dont work for everyone and require ongoing treatment.
The CRISPR approach, if successful, would be a one-time treatment. That is, by targeting the genes themselves, the protein is permanently silenced.
Patrick Doherty, a trial participant, told NPR he jumped at the opportunity.
Doherty, an avid trekker and hiker, was diagnosed with transthyretin amyloidosiswhich had killed his fatherafter noticing symptoms, like tingling fingers and toes and breathlessness on walks.
Its [a] terrible prognosis, he said. This is a condition that deteriorates very rapidly. Its just dreadful.
Doherty started feeling better a few weeks after the treatment and said improvements have continued.
A one-hit wonder, he called it. A two-hour process, and thats it for the rest of your life.
Although the results are promising, theres reason to temper expectations.
The trial, as noted was small, and focused on safety. Future work will further test safety and efficacy in larger groups, whichas is apparent from recent experience with covidcan reveal rare side effects or prove disappointing despite early success.
Researchers will likely also look out for off-target snips in the liver or other cells. A benefit of this approach, however, is the cells break down the mRNA after theyve made the Cas9 protein. In other words, the gene-editing system doesnt persist long.
It also remains to be seen whether the approach would work as well in other diseases. The liver was a prime target for the trial because it greedily soaks up foreign substances. Other organs and tissues may not be as amenable to a general infusion of the therapy.
Finally, the treatment may come with a hefty price tag, perhaps running into the hundreds of thousands of dollars according to Bloomergs Sam Fazeli.
Not one person in my field is doing a victory lap, even around their laboratory bench,Fyodor Urnov, a University of California, Berkeley gene editing expert, told US Today. Were all slightly blue because were all holding our breath.
If the trial does prove successful, however, researchers will want to know if they can reach any organ or target tissue with a general infusion. And can genes also be edited in vivo? Instead of merely knocking out a faulty gene, can we safely correct it?
In the future, when the kinks have been worked out and the science more thoroughly proven, Urnov said, gene editing could help millions of people around the world with genetic conditions. And this trial, it seems, is a notable step in that direction.
Image Credit: NIH
Read the original here:
Breakthrough CRISPR Gene Therapy Could Be a 'One and Done' Injection - Singularity Hub
- Singularity Future Technology Ltd (SGLY) is up 43.55% Tuesday In Premarket Trading - InvestorsObserver - March 18th, 2024 [March 18th, 2024]
- This Week's Awesome Tech Stories From Around the Web (Through March 16) - Singularity Hub - March 18th, 2024 [March 18th, 2024]
- Palia reaches over 3m players in six months thanks to "invaluable" Switch partnership - GamesIndustry.biz - March 18th, 2024 [March 18th, 2024]
- Beyond the Singularity: Exploring the Fusion of AI and Art - Hong Kong Standard - March 18th, 2024 [March 18th, 2024]
- Your Comprehensive Guide to Telos Staking Success | by Pizza Singularity Sapphire | Feb, 2024 - Medium - February 20th, 2024 [February 20th, 2024]
- BTS' Kim Taehyung's 'Singularity' Performance Featured in Harvard Professor's Book - BNN Breaking - February 20th, 2024 [February 20th, 2024]
- Title: Understanding the Singularity: Unveiling the Future of Humanity - Medium - December 12th, 2023 [December 12th, 2023]
- What happens at the center of a black hole? - Astronomy Magazine - December 12th, 2023 [December 12th, 2023]
- IBM Is Planning to Build Its First Fault-Tolerant Quantum Computer by 2029 - Singularity Hub - December 12th, 2023 [December 12th, 2023]
- 22 Laws of Singularity And How You Can Apply Them To Live A Better Life - Medium - December 12th, 2023 [December 12th, 2023]
- Singularity: Here's When Humanity Will Reach It, New Data Shows - March 31st, 2023 [March 31st, 2023]
- sentinelOne expands singularity marketplace with new SOAR, insider threat, training, and prioritization integrations - ZAWYA - March 31st, 2023 [March 31st, 2023]
- Reaching the Singularity May be Humanitys Greatest and Last ... - March 4th, 2023 [March 4th, 2023]
- Singularity: Explain It to Me Like I'm 5-Years-Old - Futurism - March 4th, 2023 [March 4th, 2023]
- SINGULARITY FUTURE TECHNOLOGY LTD. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in... - March 4th, 2023 [March 4th, 2023]
- Apple co-founder Steve Wozniak on Artificial Intelligence: Not worried about The Singularity, well still be in control - MacDailyNews - February 12th, 2023 [February 12th, 2023]
- Cauchy principal value - Wikipedia - January 4th, 2023 [January 4th, 2023]
- Singularity Future Technology Ltd. (SGLY) Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Against Singularity Future Technology... - December 14th, 2022 [December 14th, 2022]
- ROSEN, A LEADING LAW FIRM, Encourages Singularity Future Technology Ltd. f/k/a Sino-Global Shipping America Ltd. Investors to Secure Counsel Before... - December 12th, 2022 [December 12th, 2022]
- Singularity (mathematics) - Wikipedia - November 23rd, 2022 [November 23rd, 2022]
- GitHub: Where the world builds software GitHub - November 21st, 2022 [November 21st, 2022]
- Review: The Singularities, by John Banville - The New York Times - October 25th, 2022 [October 25th, 2022]
- We need to manage AI better as we are approaching the Creative Singularity - RedShark News - October 15th, 2022 [October 15th, 2022]
- This Week's Awesome Tech Stories From Around the Web (Through October 15) - Singularity Hub - October 15th, 2022 [October 15th, 2022]
- Ferguson: A second helping of QB play from Thanksgiving weekend - CFL.ca - October 15th, 2022 [October 15th, 2022]
- Kanimozhi slams Union govt over conducting CGL exams in only Hindi and English - The News Minute - October 15th, 2022 [October 15th, 2022]
- New Bayonetta 3 Trailer Reveals An In-Universe Singularity, And Lots Of Witches - Gameranx - October 13th, 2022 [October 13th, 2022]
- Singularity Future Technology Announces Receipt of Nasdaq Notice of Delisting and Intention to Request Hearing - Yahoo Finance - October 13th, 2022 [October 13th, 2022]
- Six Recent Discoveries That Have Changed How We Think About Human Origins - Singularity Hub - October 13th, 2022 [October 13th, 2022]
- This AI Uses a Scan of Your Retina to Predict Your Risk of Heart Disease - Singularity Hub - October 13th, 2022 [October 13th, 2022]
- The Moon May Have Formed Just Hours After Earth Collided With a Protoplanet - Singularity Hub - October 13th, 2022 [October 13th, 2022]
- UK HealthCare hosting 2 nationally esteemed guests for 60th anniversary symposium - UKNow - October 13th, 2022 [October 13th, 2022]
- Why Transcend Fund believes the opportunity for game investments is only getting bigger - VentureBeat - October 13th, 2022 [October 13th, 2022]
- Austin Powers References in This Fool, Ramy, Bros - Vulture - October 13th, 2022 [October 13th, 2022]
- Bayonetta 3 Everything You Need to Know About this Bewitching Beat em Up - Wccftech - October 8th, 2022 [October 8th, 2022]
- Longtermism: The Future Is VastWhat Does This Mean for Our Own Life? - Singularity Hub - October 8th, 2022 [October 8th, 2022]
- Ohio creates elections integrity office while voter fraud is already 'exceedingly rare' - ideastream - October 8th, 2022 [October 8th, 2022]
- Elon Musk Warns of World War III - TheStreet - October 8th, 2022 [October 8th, 2022]
- Durga reminds us of our collective obligations - Daily Pioneer - October 8th, 2022 [October 8th, 2022]
- Glitch in the algorithm - The Bucknellian - October 8th, 2022 [October 8th, 2022]
- As the Robot Fry Cook Takes Over the Kitchen - Walter Bradley Center for Natural and Artificial Intelligence - October 8th, 2022 [October 8th, 2022]
- The Singularity Image Format (SIF) Selected as a Finalist in the HPCwire Readers' Choice Awards - PR Web - October 6th, 2022 [October 6th, 2022]
- The Singularity Image Format (SIF) Selected as a Finalist in the HPCwire Readers' Choice Awards - Benzinga - October 6th, 2022 [October 6th, 2022]
- The Singularity of the Dual Mandate - Federal Reserve Bank of San Francisco - October 6th, 2022 [October 6th, 2022]
- What Is the Quirk Singularity Doomsday Theory in My Hero Academia? Explained - Twinfinite - October 6th, 2022 [October 6th, 2022]
- Introduction to week 4 of Tekedia Mini-MBA: Exponential Technologies and Singularity - Tekedia - October 6th, 2022 [October 6th, 2022]
- A $500 Million International Project Will Create the Most Detailed Map of the Brain Ever - Singularity Hub - October 6th, 2022 [October 6th, 2022]
- There Are Cheaper, More Sustainable Ways Than Desalination to Meet Our Water Needs - Singularity Hub - October 6th, 2022 [October 6th, 2022]
- #3DStartup: Unlimited Tomorrow and its 3D Printed Bionic Prosthetic Arm - 3Dnatives - October 6th, 2022 [October 6th, 2022]
- First As Parody, Then As Free Speech: The Onion Goes To The Supreme Court. It's About As Awesome As You'd Suspect. - Above the Law - October 6th, 2022 [October 6th, 2022]
- 10 Hot Cyber Threat Intelligence Tools And Services In 2022 - CRN - October 6th, 2022 [October 6th, 2022]
- Nintendo comes out strong with its offering of upcoming titles - The UML Connector - October 6th, 2022 [October 6th, 2022]
- The metaverses evolutionary roots could aid its success | Mint - Mint - October 6th, 2022 [October 6th, 2022]
- The Tech That Will Push VR to the Limits of the Human Eye - Singularity Hub - September 27th, 2022 [September 27th, 2022]
- Super-Earths Are Bigger and More Habitable Than Earth, and Astronomers Are Discovering More of the Billions They Think Are Out There - Singularity Hub - September 27th, 2022 [September 27th, 2022]
- Scientists Have Long Dreamed of a Memory Prosthesis. The First Human Trials Look Promising - Singularity Hub - September 27th, 2022 [September 27th, 2022]
- NASA's DART Spacecraft Will Smack an Asteroid at 14,000 MPH Todayand You Can Watch - Singularity Hub - September 27th, 2022 [September 27th, 2022]
- Why You Should Read This: 'The Gold Coast' - Alta Magazine - September 27th, 2022 [September 27th, 2022]
- The Multitude of Stromae - Mail and Guardian - September 27th, 2022 [September 27th, 2022]
- Warhammer 40,000: Space Marine is Getting a Location-based VR Experience Next Year - Road to VR - September 27th, 2022 [September 27th, 2022]
- What the pandemic taught us about teaching (On the Other Hand) - Montclair Local - September 27th, 2022 [September 27th, 2022]
- Where to get the Boom Sniper in Fortnite Chapter 3 Season 4 - The Nerd Stash - September 27th, 2022 [September 27th, 2022]
- Machine learning has predicted the winners of the Worlds - CyclingTips - September 27th, 2022 [September 27th, 2022]
- Vaonis Vespera Review: Easy To Use But with Underwhelming Results - PetaPixel - September 27th, 2022 [September 27th, 2022]
- The biggest problem with gravity and quantum physics - Big Think - September 27th, 2022 [September 27th, 2022]
- V gets inked on his butt cheek? BTS star spills the details about his friendship tattoo - Zoom TV - September 27th, 2022 [September 27th, 2022]
- Robots & Humans: Are we heading towards Singularity? - INDIAai - September 20th, 2022 [September 20th, 2022]
- This Week's Awesome Tech Stories From Around the Web (Through September 17) - Singularity Hub - September 20th, 2022 [September 20th, 2022]
- A Swedish Company Wants to Transform Offshore Wind With Vertical-Axis Turbines - Singularity Hub - September 20th, 2022 [September 20th, 2022]
- Decarbonizing the Energy Sector by 2050 Could Save the World $12 Trillion - Singularity Hub - September 20th, 2022 [September 20th, 2022]
- This Sleek Solar Car Goes 600 Miles on a Charge and Is Gearing Up for Production - Singularity Hub - September 20th, 2022 [September 20th, 2022]
- Meta Built an AI That Can Guess the Words You're Hearing by Decoding Your Brainwaves - Singularity Hub - September 20th, 2022 [September 20th, 2022]
- Gory Throwback FPS 'Prodeus' Exits Early Access This Thursday, Launching for PC and Consoles [Trailer] - Bloody Disgusting - September 20th, 2022 [September 20th, 2022]
- Meet the New Vespera Telescope From Vaonis - Universe Today - September 20th, 2022 [September 20th, 2022]
- Of God and Machines - The Atlantic - September 20th, 2022 [September 20th, 2022]
- Humans Destroyed Forests for Thousands of Years. We Can Become the First Generation to Expand Them - Singularity Hub - September 20th, 2022 [September 20th, 2022]
- Intel Core i9-13900K beats the 12900K by +10% in CPU-bound games - KitGuru - September 20th, 2022 [September 20th, 2022]
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Singularity Future Technology Ltd. with Losses of $100000 to Contact the Firm -... - August 15th, 2022 [August 15th, 2022]
- How To Open Singularity Rock in Tower of Fantasy - Attack of the Fanboy - August 15th, 2022 [August 15th, 2022]
- Intel i9-13900K Tested in Ashes Of The Singularity, Offers Neglible Increments in Performance - Appuals - August 15th, 2022 [August 15th, 2022]